RhumbLine Advisers
MLYS icon

RhumbLine Advisers’s Mineralys Therapeutics MLYS Stock Holding History

RhumbLine Advisers’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Buy
70,205
+12,761
+22% +$350K ﹤0.01% 1966
2026
Q1 		$1.56M Buy
57,444
+3,160
+6% +$92.7K ﹤0.01% 1987
2025
Q4 		$1.97M Sell
54,284
-1,007
-2% -$40.4K ﹤0.01% 1885
2025
Q3 		$2.1M Buy
55,291
+1,695
+3% +$36.7K ﹤0.01% 1885
2025
Q2 		$725K Buy
53,596
+14,235
+36% +$206K ﹤0.01% 2424
2025
Q1 		$625K Sell
39,361
-1,195
-3% -$13.7K ﹤0.01% 2424
2024
Q4 		$499K Buy
40,556
+695
+2% +$9.09K ﹤0.01% 2679
2024
Q3 		$483K Sell
39,861
-1,218
-3% -$14.7K ﹤0.01% 2720
2024
Q2 		$481K Buy
41,079
+18,519
+82% +$233K ﹤0.01% 2708
2024
Q1 		$291K Buy
22,560
+2,091
+10% +$25.8K ﹤0.01% 2994
2023
Q4 		$176K Buy
20,469
+3,295
+19% +$25.9K ﹤0.01% 3245
2023
Q3 		$163K Buy
17,174
+2,279
+15% +$29.7K ﹤0.01% 3262
2023
Q2 		$254K Buy
14,895
+3,935
+36% +$58.8K ﹤0.01% 3108
2023
Q1 		$172K Buy
+10,960
New +$184K ﹤0.01% 2769

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

RhumbLine Advisers's MLYS Position: Q2 2026 in Review

RhumbLine Advisers increased its Mineralys Therapeutics (MLYS) stake by 22% in Q2 2026, buying an estimated $350K and bringing the position to 70,205 shares worth $1.89M. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

RhumbLine Advisers first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.1M in Q3 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • RhumbLine Advisers held 70,205 shares of Mineralys Therapeutics worth $1.89M as of Q2 2026.
  • RhumbLine Advisers bought 12,761 Mineralys Therapeutics shares in Q2 2026, an estimated $350K.
  • Mineralys Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1966 holding.
  • RhumbLine Advisers first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • RhumbLine Advisers's Mineralys Therapeutics position peaked at $2.1M in Q3 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.